Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 2/20 | 0.37 |
| ▸ | SKP1 | P63208 | 2/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233316 | 0.86 | CKS1B (0.43) | CKS1BSKP1SKP2MEN1KMT2A | |
| SCHEMBL1232779 | 0.83 | TLR7 (0.38) | BACE1MEN1KMT2AESR2USP30 | |
| SCHEMBL205088 | 0.83 | BACE1 (0.34) | CYP8B1CKS1BSKP1SKP2BACE1 | |
| SCHEMBL1233682 | 0.83 | CYP8B1 (0.44) | CYP8B1 | |
| SCHEMBL1231827 | 0.80 | GBA1 (0.44) | CKS1BSKP1SKP2NR1H2MAPT | |
| SCHEMBL1233856 | 0.77 | MAP4K4 (0.40) | BACE1ESR2USP30NR1H2 | |
| SCHEMBL1232944 | 0.77 | CYP8B1 (0.47) | CYP8B1 | |
| SCHEMBL9968767 | 0.77 | NR1H2 (0.44) | BACE1ESR2USP30NR1H2MAPT | |
| SCHEMBL25419579 | 0.74 | NR1H2 (0.44) | BACE1ESR2USP30NR1H2MAPT | |
| SCHEMBL30138845 | 0.74 | NR1H2 (0.44) | BACE1ESR2USP30NR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888349-B2 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | CYP8B1 3218/4885CKS1B 1991/4885SKP1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.